GILEAD SCIENCES

World Rank (Jul-30-2023)
154
Market Cap (Jul-30-2023)
95.871 Billion USD
World Rank (Dec-25-2022)
120
Market Cap (Dec-25-2022)
106.300 Billion USD
World Rank (Jan-07-2022)
180
Market Cap (Jan-07-2022)
89.387 Billion USD
World Rank (Jan-01-2021)
200
Market Cap (Jan-01-2021)
73.031 Billion USD
Annual Revenue in USD
27,281 Million USD
Annual Net Income in USD
4,592 Million USD
Total Assets in USD
63,171 Million USD
Total Liabilities in USD
41,962 Million USD
Annual Results for Year ending in
Dec-2022 month
Headquarters State / City
California
Headquarters Country
USA
Headquarters Sub Region
Northern America
Headquarters Continent
Americas
Company Business
Healthcare
Biotechnology
Biopharmaceutical
Pharmaceutical
HealthCare Products
Stock Category
S&P 500
Nasdaq 100
Stock Exchange
Nasdaq
Bovespa Brazil
Company Rank in Country in 2022
Company Rank in USA in 2022 is 104
Rank in Country (Jan-2021)
Company Rank in USA in 2021 is 109
Rank in Country (Jan-2020)
Rank in USA in 2020 is 78
Number of Employees
17,000
Employee Count as on Date
As on 2022
Chairman
Daniel ODay
CEO:
Daniel O'Day
Founders
Michael L. Riordan
Yahoo @ Nasdaq
Wikipedia
Facebook
Company Website:
Gilead - Biopharmaceutical companies
Business Sector:
Top Technology Companies in USA
Top Healthcare Companies in USA
Top Technology Companies in S&P 500
Top Healthcare Companies in S&P 500
Top Pharmaceutical Companies in USA
Top Pharmaceutical Companies in S&P 500
Top Bio Pharmaceutical Companies in USA
About Company Business:

GILEAD SCIENCES INC is world’s largest bio-pharmaceutical companies. As on Dec-2021, Gilead Sciences had 14,400 employees across six continents and headquarters is in USA,

As on 2022, GILEAD SCIENCES INC has 17,000 employees.

GILEAD SCIENCES INC annual revenue generated for period ending Dec-2022 was 27,281 million USD.

GILEAD SCIENCES INC annual net loss generated for period ending Dec-2022 was 4,592 million USD.

Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead Sciences strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigation drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

GILEAD SCIENCES INC  annual revenue generated for period ending Dec-2021 was 27,305 million USD.

Split of Annual Revenue by business segment  for period ending Dec-2021:

  • Product sales: 27,008 million USD.
  • Royalty, contract and other revenues: 297 million USD.

GILEAD SCIENCES INC  annual net income generated for period ending Dec-2021 was 6,225  million USD.

Total Assets as on Dec-2021 was 67,952 Million USD

IPO Year
1992
Founded Year
1987
Annual Results Summary:

Gilead Sciences - Annual Results - Revenue and Net Income - in Million USD:

Year - Ending Revenue Operating Income Net Income
Dec-2022 27,281 10,974 4,592
Dec-2021 27,305 9,918 6,225
Dec-2020 24,689 9,927 123
Dec-2019 22,449 4,287 5,386
Dec-2018 22,127 8,200 5,455
Dec-2017 26,107 14,124 4,628
Balance Sheet Summary

Gilead Sciences - Balance Sheet Summary - in Million USD:

Year Ending: Total Assets Total Liabilities Total Equity
Dec-2022 63,171 41,962 21,209
Dec-2021 67,952 46,888 21,064
Dec-2020 68,407 50,205 18,202
Dec-2019 61,627 39,102 22,525
Dec-2018 63,675 42,288 21,387
Dec-2017 70,283 49,841 20,442
Quarterly Results Summary:

Gilead Sciences - Quarterly Results - Revenue and Net Income - in Million USD:

Quarterly Ending: Total Revenue Operating Income Net Income
Jun-2023 6,599 1,901 1,045
Mar-2023 6,352 2,185 1,010
Dec-2022 7,389 5,125 1,640
Sep-2022 7,042 3,285 1,789
Jun-2022 6,260 2,359 1,144
Mar-2022 6,590 197 19
Dec-2021 7,244 940 382
Sep-2021 7,421 3,842 2,592
Jun-2021 6,217 2,246 1,522
Mar-2021 6,423 2,890 1,729
Dec-2020 7,421 2,651 1,551
Institutional Investors

Top 30 Institutional Holder Names in GILEAD SCIENCES as on MAR-31-2023

RANK Institutional Investors DATE SHARES HELD CHANGE (SHARES) CHANGE (%) VALUE (IN 1,000S)
1 BLACKROCK INC. 3/31/2023 126,556,526 -5,003,724 -3.80% $10,146,037
2 VANGUARD GROUP INC 3/31/2023 112,974,397 936,073 0.84% $9,057,157
3 CAPITAL WORLD INVESTORS 3/31/2023 76,500,240 7,607,268 11.04% $6,133,024
4 CAPITAL RESEARCH GLOBAL INVESTORS 3/31/2023 58,278,107 3,675,155 6.73% $4,672,156
5 STATE STREET CORP 3/31/2023 57,802,268 -1,139,105 -1.93% $4,634,008
6 DODGE & COX 3/31/2023 34,701,762 -1,183,390 -3.30% $2,782,040
7 GEODE CAPITAL MANAGEMENT, LLC 3/31/2023 23,765,051 -83,426 -0.35% $1,905,244
8 FMR LLC 3/31/2023 20,909,082 4,470,179 27.19% $1,676,281
9 BANK OF NEW YORK MELLON CORP 6/30/2023 17,452,922 440,718 2.59% $1,399,201
10 MORGAN STANLEY 3/31/2023 16,107,544 -1,089,406 -6.34% $1,291,342
11 NORTHERN TRUST CORP 3/31/2023 14,549,826 -392,670 -2.63% $1,166,460
12 NORGES BANK 12/31/2022 12,989,939 612,259 4.95% $1,041,403
13 PARNASSUS INVESTMENTS, LLC 6/30/2023 12,115,066 128,121 1.07% $971,265
14 AMUNDI 3/31/2023 10,625,082 437,302 4.29% $851,813
15 RENAISSANCE TECHNOLOGIES LLC 3/31/2023 10,584,216 1,381,648 15.01% $848,537
16 LEGAL & GENERAL GROUP PLC 3/31/2023 10,569,097 -117,726 -1.10% $847,325
17 GOLDMAN SACHS GROUP INC 3/31/2023 10,487,324 1,120,063 11.96% $840,769
18 ROYAL BANK OF CANADA 3/31/2023 10,244,907 -1,094,612 -9.65% $821,334
19 INVESCO LTD. 3/31/2023 10,170,461 286,994 2.90% $815,366
20 NUVEEN ASSET MANAGEMENT, LLC 3/31/2023 9,269,109 614,202 7.10% $743,104
21 DEUTSCHE BANK AG\ 3/31/2023 9,201,001 821,730 9.81% $737,644
22 DIMENSIONAL FUND ADVISORS LP 6/30/2023 9,081,737 62,444 0.69% $728,083
23 UBS ASSET MANAGEMENT AMERICAS INC 3/31/2023 8,904,953 -468,432 -5.00% $713,910
24 ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 3/31/2023 8,191,201 -24,833 -0.30% $656,689
25 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 6/30/2023 7,946,563 -236,709 -2.89% $637,076
26 BANK OF AMERICA CORP /DE/ 3/31/2023 7,699,263 115,510 1.52% $617,250
27 WELLS FARGO & COMPANY/MN 3/31/2023 7,601,514 -590,186 -7.21% $609,413
28 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 3/31/2023 7,401,649 -147,480 -1.95% $593,390
29 ALLIANCEBERNSTEIN L.P. 3/31/2023 6,985,819 3,096,039 79.59% $560,053
30 BARCLAYS PLC 6/30/2023 6,642,910 2,126,182 47.07% $532,562

Comments

Gilead Sciences planning to acquire IMMUNOMEDICS for 21B USD

IMMUNOMEDICS share price surged by 97% on Monday trade as Gilead Sciences planning to acquire IMMUNOMEDICS for 21 Billion USD.

IMMUNOMEDICS is a biotechnology company related to cancer drugs. Headquarters is in New Jersey, USA.

Tue, 15/09/2020 - 09:40

Gilead Sciences medicine Remdesivir is approved by FDA of USA as Covid-19 medicine

Gilead Sciences medicine Remdesivir is approved by FDA of USA as Covid-19 medicine.

So there is high possibility of significant improvement can be seen in Gilead Sciences Revenues for next 2 quarters untill the World gets Covid-19 vaccine.

Gilead Sciences share price surged by 2.72%.

Fri, 23/10/2020 - 14:26

Share it on Social Media